Acta Med. 2019, 62: 127-130

Interactions Between Anti-Vegf Therapy and Antitumor Immunity as a Potential Therapeutic Strategy in Colorectal Cancer

David Bukaa, Josef Dvořákb, Igor Richterc, Pavel Škrobánekb, Tomáš Buchlerb, Bohuslav Melichard

aDepartment of Oncology and Radiotherapy, Charles University Medical School and Teaching Hospital, Hradec Králové, Czech Republic
bDepartment of Oncology, First Medical Faculty, Charles University and Thomayer Hospital, Prague, Czech Republic
cDepartment of Oncology, Regional Hospital, Liberec, Czech Republic
dDepartment of Oncology, Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic

Received March 13, 2019
Accepted June 24, 2019

There is a growing corpus of evidence indicating that anti-VEGF therapy may normalize the abnormal tumor vasculature with the potential to re-program the tumor immune microenvironment to a more immunosupportive profile. Tumor vessel normalization increases tumor perfusion, and, consequently, oxygen and nutrient supply, and thus can be assumed to improve the general response to anticancer immunotherapy. The increased antitumor immunity responses seen following anti-VEGF therapy may also be associated with the inhibition of the immunosuppressive action deployed by VEGF on effector T cells. Bearing in mind the recent advances of combination immunotherapy, combinations of anti-VEGF therapy with immune checkpoint inhibitors now appear to represent an attractive strategy. Key to the successful implementation of a combination strategy for treating cancer is understanding the interaction of these two therapeutic interventions, particularly in regards to appropriate reprogramming of the tumor immune microenvironment to improve antitumor immunity.


This study was supported by MH CZ-DRO (TH, 0064190).


21 live references